<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Many studies have demonstrated that <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> is not purely an antiplatelet agent but also exerts its antithrombotic properties through the vessel wall </plain></SENT>
<SENT sid="1" pm="."><plain>Using a laboratory model in which bovine endothelial cells are seeded to form a subendothelial matrix (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>), investigators have shown that <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> enhances the antithrombotic action of the endothelium, probably by increasing intracellular levels of cAMP and cGMP through phosphodiesterase inhibition </plain></SENT>
<SENT sid="2" pm="."><plain>If so, the antithrombotic action of <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> should also be observable away from the endothelium itself, i.e., a near-field effect </plain></SENT>
<SENT sid="3" pm="."><plain>To test this hypothesis, we reseeded the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e> with a monolayer of human umbilical vein endothelial cells (hUVECs), occluding a portion of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e> with <z:chebi fb="21" ids="53251">teflon</z:chebi> stops </plain></SENT>
<SENT sid="4" pm="."><plain>We then treated the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e> with and without hUVECs with various doses of <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> and exposed them to whole blood under flow conditions </plain></SENT>
<SENT sid="5" pm="."><plain>Human endothelial cells cultured on the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e> increased its ability to reduce <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in the adjacent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="4653">Dipyridamole</z:chebi> enhanced this antithrombotic effect of hUVECs in a dose-dependent manner </plain></SENT>
<SENT sid="7" pm="."><plain>No increment in antithrombotic effect was seen in <z:chebi fb="0" ids="4653">dipyridamole</z:chebi>-treated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e> without hUVECs </plain></SENT>
<SENT sid="8" pm="."><plain>We therefore conclude that endothelial cells have near-field antithrombotic properties that are enhanced by <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Possible explanations for the near-field enhancement effect of <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> are discussed in light of the published literature </plain></SENT>
</text></document>